Cost-utility analysis of community occupational therapy in dementia (COTiD-UK) versus usual care: Results from VALID, a multi-site randomised controlled trial in the UK

被引:2
|
作者
Pizzo, Elena [1 ]
Wenborn, Jennifer [2 ,3 ]
Burgess, Jane [3 ]
Mundy, Jacqueline [4 ]
Orrell, Martin [5 ]
King, Michael [2 ,6 ]
Omar, Rumana [6 ,7 ]
Morris, Stephen [8 ]
机构
[1] UCL, Dept Appl Hlth Res, London, England
[2] UCL, Div Psychiat, London, England
[3] North East London NHS Fdn Trust NELFT, Res & Dev Dept, London, England
[4] North East London NHS Fdn Trust NELFT, Essex Stroke Hub Team, London, England
[5] Univ Nottingham, Inst Mental Hlth, Nottingham, England
[6] UCL, Fac Brain Sci, Priment Clin Trials Unit, London, England
[7] UCL, Dept Stat Sci, London, England
[8] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England
来源
PLOS ONE | 2022年 / 17卷 / 02期
关键词
QUALITY-OF-LIFE; UNCERTAINTY; FRAMEWORK; EUROQOL; PEOPLE; GIVERS; DEMQOL;
D O I
10.1371/journal.pone.0262828
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background A community-based occupational therapy intervention for people with mild to moderate dementia and their family carers: the Community Occupational Therapy in Dementia-UK version (COTiD-UK); and Treatment as usual (TAU) were randomly assigned to 468 pairs (each comprising a person with dementia and a family carer) in the Valuing Active Life in Dementia (VALID) randomised controlled trial (RCT). Objectives To compare the cost-utility of the COTiD-UK intervention compared to TAU, using data from the VALID RCT. Methods We performed a cost-utility analysis estimating mean costs and quality adjusted life years (QALYs) per person with dementia and carer for both treatments over a 26 weeks' time horizon based on resource use data and utility values collected in the trial. Results Taking the National Health Service and Personal Social Services perspective, including costs and benefits to the person with dementia only, measuring Health Related Quality of Life based on Dementia Quality of Life scale (DEMQOL), accounting for missing data and adjusting for baseline values, there was a significant difference in costs between COTiD-UK and TAU (mean incremental cost for COTiD-UK 784 (95% CI 233 pound to 1334)) pound, but no significant difference in outcomes (mean QALYs gained 0.00664 (95% CI -0.00404, 0.01732)). The Incremental Net Monetary Benefit (INMB) for COTiD-UK versus TAU was negative at a maximum willingness to pay for a QALY of 20000 pound (mean -651 pound, 95% CI -878 pound to -424) pound or 30000 pound (mean -585 pound, 95% CI -824 pound to -345) pound. Extensive sensitivity analyses confirmed the results. Conclusions This community-based occupational therapy intervention has a very low probability of being cost-effective.
引用
收藏
页数:14
相关论文
共 40 条
  • [21] A UK multi-centre trial-based cost-utility analysis of surgical stabilisation of the spine versus intensive rehabilitation for treatment of chronic low back pain patients
    Rivero-Arias, O
    Campbell, H
    Gray, A
    VALUE IN HEALTH, 2003, 6 (06) : 773 - 773
  • [22] INDIVIDUAL RESPONDER ANALYSIS OF THE EFFECTIVENESS OF MANUAL THERAPY AND EXERCISE VERSUS USUAL CARE IN PATIENTS WITH CHRONIC NONSPECIFIC NECK PAIN: PRELIMINARY RESULTS OF A RANDOMISED CONTROLLED TRIAL
    Domingues, L. A.
    Pimentel-Santos, F. M.
    Cruz, E. B.
    Branco, J. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1793 - 1793
  • [23] ENHANCED SURVEILLANCE FOR THE DETECTION OF PSORIATIC ARTHRITIS IN A UK PRIMARY CARE PSORIASIS POPULATION VERSUS USUAL CARE: RESULTS AT 24 MONTHS FROM THE THE TOTAL BURDEN OF PSORIASIS (TUDOR) RANDOMISED CONTROL TRIAL
    Brown, S.
    Coates, L.
    Collier, H.
    Davies, C.
    Helliwell, P.
    Packham, J.
    Ransom, M.
    Tillett, W.
    Mchugh, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 339 - 340
  • [24] Prolonged conservative care versus early surgery in patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised controlled trial
    van den Hout, Wilbert B.
    Peul, Wilco C.
    Koes, Bart W.
    Brand, Ronald
    Kievit, Job
    Thomeer, Ralph T. W. M.
    BMJ-BRITISH MEDICAL JOURNAL, 2008, 336 (7657): : 1351 - 1354
  • [25] Cost-utility of behavioural activation for mitigating psychological impacts of COVID-19 on socially isolated older adults with depression and multiple long-term conditions compared with usual care: results from a pragmatic randomised controlled trial
    Wang, Han-, I
    Gilbody, Simon
    Littlewood, Elizabeth
    Baird, Kalpita
    Ekers, David
    Mcmillan, Dean
    Bailey, Della
    Chew-Graham, Carolyn
    Coventry, Peter
    Fairhurst, Caroline
    Hewitt, Catherine
    Parrott, Steve
    BMJ MENTAL HEALTH, 2025, 28 (01):
  • [26] Cost-utility analysis of antibiotic treatment in patients with chronic low back pain and Modic changes: results from a randomised, placebo-controlled trial in Norway (the AIM study)
    Grotle, Margreth
    Braten, Lars Christian
    Brox, Jens Ivar
    Espeland, Ansgar
    Zolic-Karlsson, Zinajda
    Killingmo, Rikke Munk
    Tingulstad, Alexander
    Grovle, Lars
    Froholdt, Anne
    Kristoffersen, Per Martin
    Wigemyr, Monica
    van Tulder, Maurits W.
    Storheim, Kjersti
    Zwart, John-Anker
    BMJ OPEN, 2020, 10 (06): : e035461
  • [27] Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma - Results from a randomised controlled trial
    Nord, E
    Wisloff, F
    Hjorth, M
    Westin, J
    PHARMACOECONOMICS, 1997, 12 (01) : 89 - 103
  • [28] Cost-utility of cognitive behavioral therapy versus US Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial
    Luciano, Juan V.
    D'Amico, Francesco
    Cerda-Lafont, Marta
    Penarrubia-Maria, Maria T.
    Knapp, Martin
    Cuesta-Vargas, Antonio I.
    Serrano-Blanco, Antoni
    Garcia-Campayo, Javier
    ARTHRITIS RESEARCH & THERAPY, 2014, 16 (05)
  • [29] The Age of BLood Evaluation (ABLE) randomised controlled trial: description of the UK-funded arm of the international trial, the UK cost-utility analysis and secondary analyses exploring factors associated with health-related quality of life and health-care costs during the 12-month follow-up
    Walsh, Timothy S.
    Stanworth, Simon
    Boyd, Julia
    Hope, David
    Hemmatapour, Sue
    Burrows, Helen
    Campbell, Helen
    Pizzo, Elena
    Swart, Nicholas
    Morris, Stephen
    HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (62) : 1 - +
  • [30] Cost-utility of a new psychosocial goal-setting and manualised support intervention for independence in dementia (NIDUS-Family) versus goal setting and routine care: an economic evaluation embedded within a randomised controlled trial
    Isaaq, Abdinasir
    Cooper, Claudia
    Vickerstaff, Victoria
    Barber, Julie A.
    Walters, Kate
    Lang, Iain A.
    Rapaport, Penny
    Orgeta, Vasiliki
    Rockwood, Kenneth
    Butler, Laurie
    Lord, Kathryn
    Livingston, Gill
    Banerjee, Sube
    Manthorpe, Jill
    Kales, Helen C.
    Budgett, Jessica
    Hunter, Rachael
    LANCET HEALTHY LONGEVITY, 2025, 6 (02):